Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

BACKGROUND: The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanercept or e...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S., Szumski, Annette, Koenig, Andrew S., Jones, Thomas V., Marshall, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771183/
https://www.ncbi.nlm.nih.gov/pubmed/29338762
http://dx.doi.org/10.1186/s13075-017-1484-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771183/
https://www.ncbi.nlm.nih.gov/pubmed/29338762
http://dx.doi.org/10.1186/s13075-017-1484-9

Ejemplares similares